ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
Dow Jones
38,589.16
-0.15%
Brent Oil
82.275
0.00%
Bitcoin
66,553.90
0.55%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tango Therapeutics Inc (TNGX) Quote

Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

NASDAQ
8.93
0.54
(6.44%)
Closed June 16 4:00PM
Delayed by 15 minutes
9.02
0.09
(1.01%)
After Hours: 7:59PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
8.93
Bid
8.42
Ask
9.00
Volume
1,301,091
8.08 Day's Range 9.12
2.88 52 Week Range 13.03
Market Cap
912.808M
Previous Close
8.39
Open
8.34
Last Trade
2
@
8.91
Last Trade Time
Financial Volume
$ 11,302,355
VWAP
8.6868
Average Volume (3m)
553,388
Shares Outstanding
101,989,696
Dividend Yield
-
PE Ratio
-8.97
Earnings Per Share (EPS)
-1
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tangotx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was $8.39. Over the last year, Tango Therapeutics shares have traded in a share price range of $ 2.88 to $ 13.03.

Tango Therapeutics currently has 101,989,696 shares outstanding. The market capitalization of Tango Therapeutics is $912.81 million. Tango Therapeutics has a price to earnings ratio (PE ratio) of -8.97.

TNGX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 06 2024
Edgar (US Regulatory)

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

June 05 2024
Business Wire

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM, May 23, 2024 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq...

May 23 2024
PR Newswire (US)

Form 8-K - Current report

May 23 2024
Edgar (US Regulatory)

Tango Therapeutics Announces Discontinuation of TNG348 Program

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical...

May 23 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 08 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.8526.12994350287.089.126.77070867.60088284CS
41.114.04853128997.839.126.466002887.22974194CS
120.9612.04516938527.979.126.465533887.47190393CS
26-1.18-11.671612265110.1113.0056.466237349.3425667CS
525.26143.3242506813.6713.032.8810493768.36690912CS
156-0.68-7.075962539029.6118.842.475230478.00987578CS
260-0.68-7.075962539029.6118.842.475230478.00987578CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

TNGX Discussion

View Posts
Monksdream Monksdream 1 month ago
TNGX under $10
👍️0
bikaver bikaver 9 months ago
Stopped out with small loss.
👍️0
bikaver bikaver 10 months ago
TNGX......Holding up well, but will tumble soon.
👍️0
bikaver bikaver 10 months ago
TNGA.....short @ 8.60 This is the strength that I wanted to see!
👍️0
bikaver bikaver 10 months ago
TNGX.....Studying the TNGX chart this evening. I'll short it at a good sign of strength if the opportunity presents itself tomorrow.
👍️0
SmokeSignals SmokeSignals 10 months ago
up $4>H.C. Wainwright Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Barclays Releases a Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Goldman Sachs Keeps Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 7, 2023TIPRANKS
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsAUGUST 7, 2023TIPRANKS
Tango Therapeutics reports Q2 EPS (23c), consensus (34c)AUGUST 7, 2023TIPRANKS
👍️0

Your Recent History

NASDAQ
TNGX
Tango Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved